Cas:26124-68-5 Glycol acid manufacturer & supplier

We serve Chemical Name:Glycol acid CAS:26124-68-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Glycol acid

Chemical Name:Glycol acid
CAS.NO:26124-68-5
Synonyms:MFCD00148011;PGA (Poly(glycolic acid)
Molecular Formula:C2H4O3
Molecular Weight:76.05140
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:265.6ºC at 760mmHg
Density:1.416g/cm3
Index of Refraction:
PSA:57.53000
Exact Mass:76.01600
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like MFCD00148011 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,PGA (Poly(glycolic acid) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,PGA (Poly(glycolic acid) Use and application,PGA (Poly(glycolic acid) technical grade,usp/ep/jp grade.


Related News: Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells. Glycol acid manufacturer In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday. Glycol acid supplier The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. Glycol acid vendor Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells. Glycol acid factory The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years.